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Abstract Endothelin-converting-enzyme-1 (ECE-1) belongs to 
the family of zinc metallopeptidases and is responsible for 
generating endothelin (ET) peptides from their inactive pre-
cursors the big endothelins (bigET). The enzyme is a type II 
integral membrane protein consisting of a short amino-terminal 
cytosolic domain of 56 amino acids, a single transmembrane 
domain and a large putative extracellular domain containing the 
catalytic site. Recombinant and native ECE-1 are expressed as a 
dimer. We have constructed a soluble form of ECE, named 
sECE*, by fusing the cleavable signal peptide of pro-opiomela-
nocortin in frame to the complete extracellular domain of human 
ECE-1. Stable expression of this construct in CHO cells resulted 
in the secretion of a fully active enzyme. In contrast to 
membrane-bound ECE, sECE* was expressed as a monomer, 
highly glycosylated, as assessed by gel filtration and Western 
blot. However, recombinant sECE* converted bigET-1 with 
similar specific activity as ECE-1 a. This activity was completely 
inhibited by phosphoramidon, but not by thiorphan and captopril. 
sECE* was active in a broad range of pH, showing an optimum 
of 6.6-6.8 for bigET-1. Thus, the extracellular domain alone is 
sufficient for conferring full ECE-1 activity, inhibitors recogni-
tion and substrate specificity. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The endothelins are a recently discovered family of three 
21-amino acid peptides that regulate vascular tone [1,2] and 
play an important role in cardio-vascular and enteric nervous 
system development [3,4]. Endothelin-2 (ET-2) and endothe-
lin-3 (ET-3) differ from endothelin-1 (ET-1) by 2 and 6 amino 
acids respectively, and are encoded by separate genes [5]. ETs 
are initially synthesized as large inactive precursor proteins 
called preproETs (212, 178 and 238 amino acids, respectively) 
which are first cleaved at two pairs of basic amino acids [6] to 
generate bigET-1, bigET-2 and bigET-3 (38—41 amino acids). 
They are then cleaved by endothelin-converting enzyme 
(ECE) (EC 3.4.24.71) at a Trp-Val (for bigET-1 and bigET-
2) or Trp-Ile (for bigET-3) site to produce the 21-residue 
active peptides [7]. 
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ECE is a key enzyme in the biosynthesis of the endothelins 
as the biological activities of bigETs are negligible [8,9]. ECE 
is a new membrane-bound metalloprotease [7,10,11] with 
structural homology to neutral endopeptidase (NEP) [12] 
and Kell blood group protein [13], displaying 39% similarity 
to NEP and 32% to Kell protein. ECE is inhibited by phos-
phoramidon but not by thiorphan, a specific inhibitor of NEP 
[14]. Two human ECE-1 isoforms, ECE-la and ECE-lb [15-
17] have recently been cloned. They differ only by their N-
terminal extremities and are encoded by a single gene [18]. 
ECE-1 is assumed to be a type II integral membrane pro-
tein with a short N-terminal cytoplasmic tail, a single trans-
membrane hydrophobic helix and a large putative extracellu-
lar domain containing the catalytic site [19]. Membrane 
preparations of Cos and CHO cells transfected with the 
cloned ECE-1 efficiently convert bigET-1 in vitro but are 
less efficient for the conversion of bigET-2 and bigET-3, sug-
gesting that this isoform is specifically implicated in bigET-1 
processing [20,21]. Recently, using a live-cell assay, Parnot et 
al. [22] showed that ECE-la is able to process bigET-1 into 
ET-1 both intracellularly (probably within vesicles) and ex-
tracellularly at the plasma membrane [22]. 
ECE-1 is a member of the zinc metalloprotease family, 
harbouring the HEXXH zinc-binding motif. Recent studies 
using site-directed mutagenesis have shown that two glutamic 
acids (residues 592 and 651) and one histidine (residue 716) 
are responsible for catalytic activity and zinc binding in rat 
ECE-la [23]. ECE exists as a dimer and this process is due to 
the sole Cys412 as shown by site-directed mutagenesis of rat 
ECE-la. It was also shown that the equivalent residue 
(Cys416) in human ECE-1 a is involved in dimerization [24]. 
The contribution of other amino acids to the catalytic activity 
is still unknown as well as the role of the cytosolic and mem-
brane-spanning domains in the transport of the protein to the 
cell surface and in the protein conformation necessary for 
catalytic activity and substrate specificity. 
The purpose of the present study was to determine the role 
of the intracellular and the transmembrane domains and to 
evaluate whether a soluble form of ECE-1 could be trans-
ported to the cell surface and secreted as an active form. 
For this purpose, the intracytoplasmic and membrane-span-
ning domains of ECE-1 were substituted by the signal peptide 
of a secretory protein (pro-opiomelanocortin) (POMC) as de-
scribed previously for NEP [25]. The resulting truncated en-
zyme is not inserted in the plasma membrane but can be 
recovered as a soluble form of ECE-1 in the culture medium 
of stably transfected CHO cells and exhibits the same enzy-
matic characteristics as the membrane-bound enzyme. Finally, 
the soluble enzyme appears predominantly as a monomer 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793(97)01323-9 
366 P. Korth et al.lFEBS Letters 417 (1997) 365-370 
compared to the membrane-bound enzyme which is expressed 
mainly as a dimer. This monomer of ECE will be a useful tool 
in structural and functional studies. 
2. Materials and methods 
2.1. Plasmid construction 
The pcDNA3 expression vector (Invitrogen) in which ECE-la was 
subcloned [22], named pcDNA3-ECE-la, was digested by HindWl 
which removed the first 287 bp of the ECE cDNA corresponding to 
the N-terminal cytoplasmatic tail and the transmembrane domain 
(amino acids 1 to 78). To create a secreted ECE (sECE*), the follow-
ing sequence was added 5'-AGCTTACTAGTATGCCGAGATCGT-
GCTGCAGCCGCTCTCGGGGGCCCTGTTGCTGGCCTTGCTG-
CTTCAGGCCTCCATGGAAGTGCGTGGCATGCAGTACCAGA-
CAAGATCCCCCTCTGTGTGCCTGAGCGA-3': The nucleotide 
sequence corresponds to the human POMC signal peptide followed 
by a Sph\ site (underlined nucleotides) and the ECE sequence corre-
sponding to the amino acids 78 to 90 (bold nucleotides) with a Hin-
dlll site added at both ends. This double stranded oligonucleotide was 
subcloned in the expression vector described above. This plasmid was 
named pcDNA3-sECE*. 
2.2. Expression in CHO cells 
CHO-K1 cells were maintained in Ham's F-12 medium supple-
mented with 10% fetal calf serum, 0.5 mM glutamine, 100 U/ml pen-
icillin and 100 |xg/ml streptomycin. To establish the CHO/ECE-la and 
CHO/sECE* clones, CHO cells were transfected with 10 ug of the 
corresponding plasmids using the calcium phosphate precipitation 
method [26]. Single colonies of primary G418-resistant (750 |ig/ml) 
transformants were isolated and first screened by RNA dot blot. 
Cell colonies expressing ECE mRNA were selected and subcloned 
using the limiting dilution technique. Pure cell lines were further as-
sayed for their ECE activity. 
2.3. Membrane preparation 
CHO cells expressing the human ECE-la were grown to confluence, 
washed twice with ice-cold PBS and collected. All subsequent steps 
were performed at 4°C. The cells were homogenized in 20 mM Tris-
HC1, pH 7.0, 5 mM MgCl2, 0.1 mM phenylmethylsulfonyl-fluoride, 20 
uM pepstatin A and 20 |xM leupeptin using a polytron homogenizer. 
The homogenate was centrifuged at 1300Xg for 10 min, and the 
resulting supernatant was further centrifuged at lOOOOOXg for 60 
min. The crude membrane pellet thus obtained was solubilized for 
60 min in the homogenization buffer containing 0.5% (w/v) Triton 
X-100 to give a final protein concentration of 2-3 ug/ml. The sample 
was centrifuged at 100 000 Xg for 60 min and the resulting superna-
tant was used as solubilized membrane. 
2.4. ECE activity assay 
Selected CHO clones expressing sECE* (CHO/sECE*) were grown 
to confluence and washed twice with PBS. 3 X106 cells were incubated 
for a 24 h period with 3 ml serum-free medium (Ultra-CHO, Bio-
Whittaker or DMEM, Boehringer) supplemented with 0.5 mM gluta-
mine, 100 U/ml penicillin and 100 ug/ml streptomycin. The medium 
was recovered, centrifuged and concentrated by ultra-filtration (Milli-
pore, Ultra-free centrifugal filter unit with a 50 000 NMWL Biomax 
high-flux polysulfone membrane). To test the stability of sECE* ac-
tivity in the two culture mediums used, bigET-1 conversion rate was 
determined under the same conditions in freshly harvested medium 
and after various storage periods at 4°C. 
The enzymatic conversion of bigET into ET peptides was carried 
out in 100 ul buffer A (50 mM Tris-HCl (pH 7.0), 150 mM NaCl, 0.1 
uM ZnCl2 and 0.1% BSA) by incubating the solubilized membrane 
protein or concentrated medium with 0.1 uM bigET-1, bigET-2 or 
bigET-3 for 15 min at 37°C, unless otherwise stated. For some experi-
ments, samples were preincubated at 37°C with various protease in-
hibitors added to buffer A, prior to the addition of bigET substrates. 
To determine IC5o of phosphoramidon various concentrations from 
0.5 (iM to 50 |iM were used. The reaction was stopped by adding 100 
JJ.1 of 5 mM EDTA and then subjected to a commercial EIA kit 
(Cayman Chemical Co., Ann Arbor, USA) to quantitate ET-1, ET-
2, or ET-3 generation. For the determination of Km values, human 
bigET-1 was used at concentrations of 50, 100, 330, 500, 667 nM, 1, 2 
and 5 uM at pH 6.8 for 30 and 60 min to keep substrate conversion 
below 10%. 
2.5. Immunological characterization of recombinant ECE-la 
and sECE* 
Antiserum 473-17-A was raised in rabbits against a synthetic pep-
tide corresponding to amino acid sequence 473^189 of the extracellu-
lar part of human ECE-la. The antisera obtained were screened by 
RIA using the 125I-labelled corresponding peptide. Preimmune serum 
of each rabbit was used for negative control. Using immunoblot anal-
ysis the crossreactivity of antiserum 473-17-A to purified NEP (a 
generous gift of Dr. G. Boileau) was examined, since comparison of 
the corresponding cDNA sequences showed high level of homology. 
The antiserum did not recognize human NEP up to a concentration of 
2 ug of pure protein when analyzed by immunoblot (data not shown). 
To further characterize this antiserum, immunoprecipitation was 
carried out after metabolic labelling of CHO/ECE-la, CHO/sECE* 
and untransfected CHO cells. Cells grown to confluence were starved 
of methionine and cysteine for 60 min and pulse-labelled for 30 min 
with 50 uCi of [35S]Pro-mix (Amersham, UK) in methionine and 
cysteine-free Ham's F-12 medium. After a 3 h chase in complete 
medium, cells were solubilized by overnight incubation in buffer B 
(50 mM Tris-HCl (pH 7.5), 150 mM NaCl, l%Triton X-100, 1 mM 
EDTA). The samples were centrifuged 12000Xg for 10 min and the 
resulting supernatant was incubated with 5 ul of polyclonal antiserum 
473-17-A and 60 ul of protein A/Sepharose (100 mg/ml, Pharmacia 
LKB) overnight at 4°C. The beads were washed once with buffer B, 
once with 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Triton X-
100, 1 mM EDTA, and once in 20 mM Tris-HCl pH 6.8. The antigen 
eluted in boiling loading buffer was resolved by 7.5% SDS/PAGE, and 
the gel was dried and subjected to autoradiography. 
Secreted and membrane-bound ECE were analyzed by SDS-PAGE 
followed by Western blot. Solubilized membrane proteins (ECE-la) or 
concentrated medium (sECE*) were resolved on a 7.5% polyacryl-
amide gel [27] and transferred to a polyvinylidene fluoride micropo-
rous membrane (Immobilon P, Millipore). Immunoelectrophoretic 
blot analysis was carried out as described [28], The primary antiserum 
was used in 1:300 dilution. In some experiments sECE* (25-30 ug) 
and ECE-la (10-15 ug) were deglycosylated using /V-Glycosidase F 
deglycosilation kit (Boehringer Mannheim), essentially as recom-
mended by the manufacturer and subjected to Western analysis. 
2.6. Gel filtration 
2 ml Ultra-CHO medium containing sECE* was dialyzed against 3 1 
of 50 mM Tris-HCl (pH 7.0) containing 100 mM NaCl and 1 uM 
ZnCl2. A 0.5 ml aliquot was applied to a Superose 12 (HR 10/30) 
column equilibrated with the same buffer used for dialysis. The col-
umn was eluted with the same buffer at a flow rate of 0.4 ml/min, and 
0.2 ml fractions were collected. All fractions were concentrated to 50 
ul using speed-vac centrifugation. The ECE activity was estimated 
after in vitro incubation of 10 ul of each fraction with 0.1 uM big-
ET-1 for 60 min as described above. Subsequently the ET-1 genera-
tion was measured by EIA. 
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Fig. 1. Schematic representation of the soluble form of ECE 
(sECE*) compared to ECE-la. Black block: membrane-spanning 
domain, dashed block: consensus zinc binding site, o : cysteine resi-
due, grey block: POMC signal peptide (24 amino acids). Numbers 
correspond to amino acid residues of human ECE-la. The polyclo-
nal antibody used in this study was made against a peptide corre-
sponding to the sequence 473^189 of human ECE-la. 
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3. Results 
3.1. Construction and expression of sECE* in CHO cells 
In order to obtain a secreted ECE, a truncated form of 
ECE was constructed by deleting the coding region of the 
cytoplasmic and membrane-spanning domains followed by 
fusing in frame the sequence of the cleavable signal peptide 
from human POMC to the coding region of the complete 
extracellular domain (amino acids 78-758) of ECE-la (Fig. 
1). Preliminary studies indicated that CHO cells showed no 
endogenous bigET-1 conversion activity and were therefore a 
suitable expression system. Stable cell lines expressing wild-
type ECE-la and sECE* were established. The recombinant 
clones expressing the highest ECE activity were chosen for 
further studies. For the detection of ECE protein an antise-
rum was raised against a synthetic peptide corresponding to 
the amino acids 473^189 of ECE-la. Specificity of the anti-
serum was tested by immunoprecipitation using the CHO/ 
ECE-la cells or the untransfected cells, as control. As shown 
in Fig. 2, in CHO/ECE-la cell lysates, the antiserum immu-
noprecipitated an antigen which migrated, in non-reducing 
conditions, as a major protein of an apparent molecular 
mass of 250-300 kDa, and a minor protein of 120 kDa. In 
presence of p-mercaptoethanol, only a broad and thick band 
around 120 kDa was observed. This pattern of bands is con-
sistent with the described homodimeric membrane-bound 
ECE-la. No immunoprecipitated radiolabelled proteins were 
detected in non-transfected CHO cells (Fig. 2). 
In CHO/sECE* conditioned media, the antiserum 473-17-A 
recognized a broad band of approximately 115 kDa indicating 
that these cells released soluble ECE (Fig. 3). No immuno-
reactive proteins were present in CHO/ECE-la and CHO con-
ditioned media (Fig. 3). Solubilized membrane proteins with 
reducing agent, revealed a broad band of 120 kDa in CHO/ 
ECE-la cell membranes, but none in non-transfected CHO 
control cells (Fig. 3). Interestingly, in CHO/sECE* mem-
branes the 120 kDa band was absent, instead, a discrete 
band of approximately 90 kDa was present. Pulse-chase ex-
periments in CHO/sECE* cells followed by immunoprecipita-
tion confirmed the time-dependent secretion of sECE* (data 
not shown). 
3.2. Characterization of enzymatic activity of sECE* 
In preliminary experiments two different culture media were 
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Fig. 2. Characterization of the polyclonal antiserum 473-17-A. Non-
transfected (NT) and CHO/ECE-la cells were pulse-labelled with 50 
uCi of [35S]methionine and cysteine for 30 min and chased for 3 h. 
Cells were solubilized and immunoprecipitated with the polyclonal 
antiserum 473-17A as described in Section 2. Immunoprecipitated 
samples were analysed by SDS-PAGE after boiling in the absence 
(—ME) or presence (+ME) of P-mercaptoethanol. The gel was ex-
posed for autoradiography. Arrows indicate the dimeric and the 
monomeric forms of the enzyme. The left lane contained 14C-la-
belled markers. 
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Fig. 3. Efficient secretion of sECE* in transfected CHO cells. The 
concentrated conditioned medium (25 ug protein) and solubilized 
membranes (15 ug protein) from non-transfected (NT), CHO/ECE-1 
and CHO/sECE* cells were analysed by Western blot using the 
ECE polyclonal antiserum 473- 17A. The amount of medium from 
CHO/sECE* and membranes of CHO/ECE-la loaded onto the gel 
had the same enzymatic activity (270 pmol/ml/min). Numbers on 
the right show the position of molecular weight markers. 
phosphoramidon concentration (log M) 
B 
PH 
Fig. 4. In vitro characterization of sECE* from CHO/sECE* condi-
tioned medium. A: Concentration-dependent inhibition of sECE* 
activity by phosphoramidon. 50 ul of CHO/sECE* conditioned me-
dium were used. B: pH profile of sECE* activity using 10 ul of 
10 X concentrated conditioned medium on isopeptide substrates. 
BigET-1 (o, • , grey circle), bigET-2 (□, ■. grey box) or bigET-3 
( A , A, grey triangle) at 100 nM were used as substrates and 
generation of corresponding mature peptides was measured by EIA. 
The pH was determined by using 50 mM buffers MES (open sym-
bols), HEPES (black symbols) and Tris HC1 (grey symbols). Specif-
icity of the reaction was tested by preincubation with 100 uM phos-
phoramidon (not shown). 
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tested for sECE* production from CHO/sECE* cells. The 
bigET-1 conversion activity was slightly higher with Ultra-
CHO compared to serum-free DMEM medium indicating a 
larger amount of sECE* secretion or a better stability. Indeed, 
full stability of sECE* in Ultra-CHO medium lasted at least 
three months, therefore Ultra-CHO medium was used in all 
subsequent experiments. Cell culture medium recovered from 
confluent CHO/sECE* cells efficiently converted bigET-1 into 
ET-1 whereas medium recovered from non-transfected CHO 
or CHO/ECE-la cells showed no detectable cleavage of big-
ET-1 (data not shown). Conversely, membrane fraction of 
CHO/ECE-la cells exhibited ECE activity whereas membrane 
fractions from CHO/sECE* or non-transfected CHO cells did 
not convert bigET-1 into ET-1 (data not shown). The soluble 
ECE activity was inhibited by phosphoramidon in a dose-
dependent manner with an apparent IC5o value of 6 LiM 
(Fig. 4A). The enzyme was not inhibited in vitro by captopril, 
thiorphan, pepstatin A, leupeptin, PMSF, E-64 or chymosta-
tin, however the chelating agents EDTA and 1,10-phenan-
throline completely inhibited ECE activity secreted from 
CHO/sECE* cells (Table 1). Recombinant sECE* converted 
bigET-1 much more efficiently than bigET-2 and bigET-3 
(Fig. 4B). Soluble ECE activity was detectable in a relative 
broad range of pH 5.0-7.0 with different maximums for the 
three bigETs (Fig. 4B). BigET-1 was most efficiently cleaved 
at pH 6.6-6.8, whereas conversion of bigET-2 and bigET-3 
showed a maximum at pH 6.0. The bigET-converting activity 
was completely blocked by 100 iiM phosphoramidon at each 
pH tested indicating that any non-specific degradation oc-
curred at low pH values. 
The enzymatic properties of sECE* were very similar to 
ECE-la. Further kinetic analyses revealed that Km for bigETl 
of the recombinant soluble enzyme was 1.98 (iM±0.87 
(mean ± S.E.M., « = 4), very similar to the membrane anch-
ored enzyme (8.03 pM±2.05 (n-2) determined in the same 
experiments). Moreover, it is interesting to notice that when 
the same activity was loaded into a gel, an immunoreactive 
band with comparable intensity was revealed (Figs. 3 and 6). 
3.3. Estimation of molecular mass of sECE* 
Size-exclusion chromatography was performed to estimate 
the apparent molecular mass of native soluble ECE. Using a 
FPLC superose 12 column, sECE* activity eluted as a single 
peak, corresponding to a molecular mass of 110-140 kDa 
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Fig. 5. Determination of molecular mass of native sECE*. A: 
FPLC analysis of sECE*. 0.5 ml of CHO/sECE* medium was ap-
plied to a Superose 12 HR10/30 column. 0.2 ml fractions were col-
lected and analyzed. ECE activity was estimated after incubation of 
1/5 of each fraction with 0.1 uM bigET-1 for 60 min in absence (•) 
or presence of 100 |xM phosphoramidon (■). Arrows indicate the 
elution positions of ferritin (440 kDa), catalase (232 kDa), aldolase 
(158 kDa), bovine serum albumin (67 kDa), and chymotrypsine (25 
kDa). B: Western blot of 10 ill of 30X concentrated CHO/sECE* 
medium and 15 ug of CHO/ECE-la membranes. Samples boiled in 
SDS gel sample buffer in the presence (+) and absence (—) of P-
mercaptoethanol (ME) were subjected to SDS-PAGE and analyzed 
by immunoblotting using antiserum 473-17A. Arrow indicates the 
monomeric form of sECE*, arrow heads the monomeric and dimer-
ic forms of full length ECE-la for comparison. Lines on the right 
show the position of molecular weight markers. 
(Fig. 5A). sECE* activity was totally inhibited by preincubat-
ing the fractions in the presence of 100 uM phosphoramidon 
confirming the specificity of the assay (Fig. 5A). 
In addition, in contrast to ECE-la, sECE* appeared as a 
Table 1 
Inhibition profile of sECE* activity 
Compound Concentration (|iM) ECE activity (% of control) 
EDTA 
1,10-Phenanthroline 
Thiorphan 
Captopril 
PMSF 
E-64 
Chymostatin 
Pepstatin A 
Leupeptin 
1 
10 
10 
100 
10 
50 
10 
50 
100 
50 
100 
20 
20 
47 
8 
10 
0 
96 
79 
99 
90 
103 
101 
106 
111 
93 
The indicated amount of inhibitor were preincubated for 15 min at 37°C in 100 ul of ECE assay buffer with 5 ul of 10 X concentrated medium from 
CHO/sECE* before the addition of 0.1 |iM 5 mM EDTA. 2 |il of reaction mixture was tested for ET-1 concentration in EIA. Control activity 
(100%) was determined in the absence of inhibitors. Data are the means of two independent experiments. 
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Fig. 6. Deglycosylation of sECE* and ECE-la. Recombinant 
sECE* and ECE-la enzymes were mock treated (—) or treated with 
2 units of endoglycosidase F (+), under reducing conditions and an-
alysed by Western blot. The amount of medium from CHO/sECE* 
cells and membranes of CHO/ECE-la cells loaded onto the gel had 
the same enzymatic activity (430 pmol/ml/min). Lines on the right 
show the position of molecular weight markers. 
broad band with an apparent molecular mass of 115 kDa 
regardless of the presence of (3-mercaptoethanol (Fig. 5B). 
Deglycosylation of ECE-la and sECE* with endoglycosidase 
F resulted in both cases in single sharp bands of 80 and 70 
kDa respectively (Fig. 6). 
4. Discussion 
The two human ECE-1 isoforms, which differ only by their 
N-terminal intracellular regions, are encoded by a single gene 
[18]. The two isoforms seem to have the same specific activity 
of cleavage of bigET-1 to generate ET-1 [16]. Until now, no 
biological soluble form of ECE has been characterized, 
although Takada et al. [29] reported the presence of a phos-
phoramidon-sensitive ECE in the cytosolic fraction of bovine 
endothelial cells. Therefore, it was interesting to create a solu-
ble form of ECE-1 to investigate its biochemical charac-
teristics. Like NEP, ECE-1 is a class II integral membrane 
protein with a short N-terminal cytoplasmic tail, a trans-
membrane domain that represents the uncleaved signal pep-
tide, and a large putative extracellular domain. 
The aim of this work was to determine if a recombinant 
soluble form of ECE-1 containing only the extracellular do-
main, retains enzymatic activity. To construct a soluble form 
of ECE-1, the same strategy as Lemay et al. [25] for solubiliz-
ing NEP was used by substituting the cytoplasmic and mem-
brane-spanning domains of ECE for the signal peptide of 
POMC, a secretory protein. It was expected that the in frame 
fusion of the POMC signal peptide would direct the routing of 
ECE devoid of its membrane domain through the secretory 
apparatus and allow its secretion in the extracellular medium. 
The polyclonal antibody raised against a peptide corre-
sponding to amino acids 473^-89 of the extracellular part of 
ECE recognizes specifically both forms (the membrane-bound 
and soluble) of ECE-1 without background staining of un-
transfected cells. By comparison to the CHO/ECE-la cell 
membranes, CHO/sECE* cell membranes had no immuno-
reactive 120 kDa band, indicating that ECE devoid of its mem-
brane domain is efficiently secreted into the culture medium. 
The catalytic and biochemical properties of the soluble en-
zyme recovered in the culture medium of CHO/sECE* cells 
were determined using an in vitro enzymatic assay. The ob-
served high stability of sECE* in Ultra-CHO culture medium 
demonstrated that the CHO/sECE* cell line was a useful tool 
to produce large amounts of sECE* without the need to pu-
rify it for studying its enzymatic properties. We show that, in 
our expression system, sECE* containing medium and CHO/ 
ECE-la membrane fractions exhibit the same enzymatic prop-
erties. sECE* activity was inhibited dose dependently by 
phosphoramidon but not by thiorphan, a specific NEP inhib-
itor [14] nor by captopril, a specific ACE inhibitor [30]. More-
over, sECE* was not blocked by inhibitors of serine, aspartic 
or cysteine peptidases but completely inhibited by the chelat-
ing agents EDTA and 1,10-phenanthroline, showing that the 
soluble ECE keeps all the characteristics of zinc metallopro-
teases. These results demonstrate that the soluble form of 
ECE-1 exhibits the same properties versus the inhibitors as 
the membrane form, ECE-la. Therefore, we conclude that 
neither the intracellular nor the transmembrane domain play 
a role in inhibitor binding. 
sECE* also kept the properties of substrate specificity as it 
cleaved preferentially bigET-1 versus bigET-2 and bigET-3. 
The similar Km for bigET-1 and the comparable amount of 
protein revealed on Western blot for the same activity dem-
onstrates that the specific activity of both, soluble and full 
length enzymes, appear to be identical. Also, pH activity 
range differed not much between the two enzymes. sECE* 
was active in a broad range of pH showing still 50% of ac-
tivity at pH 5.0 and a pH optimum between 6.6 and 6.8 for 
cleaving bigET-1. For the first time, the pH optimum for 
bigET-2 and bigET-3 conversion was examined which was 
6.0 for both substrates. However, at each pH tested, sECE* 
cleaved preferentially bigET-1. These results therefore demon-
strate that anchoring of the ectodomain into the plasma mem-
brane is neither important for the catalytic activity of ECE 
nor for its substrate recognition. 
The purified rat lung ECE-1 and the recombinant ECE-la 
expressed in Cos cells are both composed of two disulfide-
linked subunits [31]. Recent analysis using site-directed muta-
genesis revealed that Cys416 in human ECE-1 is responsible 
for dimer formation, and that this dimerisation favours con-
version of bigET-1 into ET-1 [23,24]. In the present study, in 
contrast to the membrane-bound ECE-la, soluble ECE ap-
peared as a monomer on gel filtration and Western blot. 
Nevertheless, sECE* kinetic parameters did not differ signifi-
cantly from the wild-type enzyme indicating that dimerization 
does not appear to be essential nor preferential for full ECE 
activity. 
Faster electrophoretic mobility of recombinant sECE*, in-
dicating an apparent molecular mass lower than ECE-la is in 
accordance with the theoretical size of the truncated protein 
(78 amino acids less) which seems to be indeed cleaved at the 
site of the signal peptide. The difference was still visible after 
deglycosylation, suggesting that both enzymes are quantita-
tively similarly glycosylated, even though slightly altered gly-
cosylation pattern cannot be ruled out with the present data. 
The apparent molecular mass after deglycosylation for both 
enzymes is consistent with the expected size according to the 
sequence. The maintenance of the same glycosylation level of 
the soluble ECE compared to the membrane-bound enzyme 
may be important for activity since it has been demonstrated 
for NEP, that transport to the cell surface and enzymatic 
activity are both dependent on sugar residues of NEP prob-
ably through conformational constraints [32]. 
Purification of large amounts of membrane-bound ECE has 
been particularly difficult due to the detergent requirement in 
all separation steps, as well as the risk of contamination of the 
370 P. Korth et al.lFEBS Letters 417 (1997) 365-370 
preparat ion with unspecific ET degrading activities and the 
impaired stability of enzyme activity. This recombinant solu-
ble E C E will be easily purified from the incubation medium of 
cultured cells without the use of detergent. This enzyme kept 
the same enzymatic properties as the membrane-bound ECE-
1. A well-characterized soluble form of endothelin-converting 
enzyme is of interest for further structural studies by site-di-
rected mutagenesis, development and easy screening of inhib-
itors and eventually crystallization. 
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